Screen Reader Access



Notices


Message from Director


CSIR – Central Drug Research Institute, Lucknow is one of the premier research institutes of India which were envisioned by the National leaders much before the independence of our nation to drive and lead the technological independence. Dedicated in the service of nation on 17 February 1951, as a constituent laboratory of Council of Scientific & Industrial Research, India, our Institute has evolved into a unique R&D organization possessing end-to-end expertise for fundamental chemical and biomedical research driven new drug discovery and development. Apart from the new drug development, the Institute is richly contributing to the advancement of our understanding of disease biology in the areas of national priorities, and set-off revolution of Indian pharma sector over the past 70 years.

Dr. Radha Rangarajan

Director, CSIR-CDRI


Research Area

CDRI
CSIR-CDRI

Development of new drugs/drug combinations as therapeutic interventions for malaria, leishmaniasis and filariasis

Development of new drugs/drug combinations as therapeutic intervention for malaria, leishmanial and filariasis


Identification of unique targets and pathways for future interventions


Investigations on parasite biology and host-parasite interactions.

cdri
CSIR-CDRI

Development of novel agents for fracture healing and management of osteoporosis through modern drug design..

Development of novel agents for fracture healing and management of osteoporosis through modern drug design, scientific validation of traditional remedies and generation of new knowledge

CDRI
cdri

The World Health Organization has defined Antimicrobial resistance as the ability of a microorganism to stop an antimicrobial from working against it..

The World Health Organization(WHO) has defined Antimicrobial resistance (AMR) as the ability of a microorganism to stop an antimicrobial from working against it. As a result, standard treatments become ineffective, infections persist and may spread to others. It has further stated “AMR is of particular concern in developing nations, including India, where the burden of infectious disease is high and healthcare spending is low. The country has among the highest bacterial disease burden in the world. Antibiotics, therefore, have a critical role in limiting morbidity and mortality in the country.

CDRI
CSIR-CDRI

Affordable drugs for lifestyle diseases (CVS,CNS and related disorders) to achieve the dream “SWASTH BHARAT”

As per the estimates in the WHO non communicable disease (NCD) Country Profile 2014, Cardio- vascular disease (CVD) is the leading cause of Deaths in India and accounts for 26% of all deaths. As per WHO more than 4% of Indian population (3rd in world after USA and China) is obese, which is the main reason of major CVDs. In 2008, WHO declared dementia/AD as a priority condition through the Mental Health Gap Action Programs


cdri
CSIR-CDRI

Development of novel therapeutic agents for CVS, CNS and related disorders, cancer, fertility regulation (male/female)..

Development of novel therapeutic agents for CVS, CNS and related disorders, cancer, fertility regulation (male/female) and management of endocrine disorders through modern drug design, scientific validation of traditional remedies

CDRI
cdri

Meiosis is the defining event of spermatogenesis. Spermatocytes undergo meiosis to give rise to round spermatids, which in turn ...

Meiosis is the defining event of spermatogenesis. Spermatocytes undergo meiosis to give rise to round spermatids, which in turn metamorphose to flagellated spermatozoa that mature in the epididymis. To characterize the dynamics of gene expression during these important stages of spermatogenesis, undertook transcriptome analysis in >90% pure pachytene spermatocytes and round spermatids, and pure mature sperm of rat by massive parallel deep sequencing.

CDRI
CSIR-CDRI

Discovery and Development of New Avenues for Cancer Therapy and Diagnosis Making Cancer Care Affordable in India

Discovery and Development of New Avenues for Cancer Therapy and Diagnosis Making Cancer Care Affordable in India

cdri
cdri

Pre-clinical and clinical development of drug substances and drug products for diseases of national importance..

Pre-clinical and clinical development of drug substances and drug products for diseases of national importance, international relevance and public health needs


Continued engagement with drug regulation and pharmaceutical policy making in India as well as internationally

Our Drugs

E-MAL Arteether

For cerebral malaria as a second line treatment for chloroquine resistant cases, licensed to Themis Chemicals Ltd., Mumbai in 1997.

Keen Mind Bacopa Extract

Keenmind is marketed through Soho Flordis International, Sydney, Australia and is available now in India.

Saheli Centchroman

First non steroidal female oral contraceptive Licensed to HLL Lifecare Ltd., in 1992 & being marketed as SAHELI.

Reunion Dalzbone

Success Story of Development of New Herbal Medication for Bone Health.


MoUs/Licenses

Facilities & Services

Events & Activities


Campus Life@ CDRI



Important Links